Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?

Department of Nuclear Medicine, Carl Gustav Carus Medical School, University of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. Thomas.Gruning@phnt.swest.nhs.uk

OBJECTIVES: To evaluate the effectiveness of isotretinoin for improving (131)I uptake in recurrent/metastasized thyroid cancer with no/insufficient (131)I uptake. DESIGN: Retrospective analysis of 25 patients treated between June 1999 and May 2001. METHODS: 15 female and 10 male patients were given isotretinoin at 1 mg/kg for 3 months, followed by (131)I treatment. All patients received a (131)I scan 72 h after administration, thyroglobulin measurement, chest X-ray and ultrasound of the neck, and some patients underwent a (18)F-fluorodeoxyglucose (FDG) positron emission tomography (n=14) and computed tomography scan of the chest (n=11). RESULTS: In two out of 14 patients with raised thyroglobulin but no (131)I uptake, a slightly improved (131)I uptake was seen. In a further 11 patients an improvement of (131)I uptake of known lesions was desired or further non-(131)I-accumulating lesions were known. A dosimetrically relevant improvement of uptake was seen in three of these patients. (18)F-FDG uptake and thyroglobulin did not correlate with the success/failure of the isotretinoin treatment. Side effects including a strong "sunburn", cheilitis, mucositis, conjunctivitis and raised transaminases occurred in two-thirds of patients. They were of an overall tolerable level and were reversible after isotretinoin had been stopped. CONCLUSION: From our clinical experience over a period of 2 years we conclude that the therapeutic effect of isotretinoin in thyroid cancer is certainly less than previously reported. An indiscriminate use of isotretinoin in all patients with otherwise untreatable thyroid cancer cannot be recommended.

This article has been cited by other articles:

				W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans Targeted therapy in nuclear medicine current status and future prospects Ann. Onc., November 1, 2007; 18(11): 1782 - 1792. [Abstract] [Full Text] [PDF]

				S. Zitzmann, S. Kramer, W. Mier, U. Hebling, A. Altmann, A. Rother, D. Berndorff, M. Eisenhut, and U. Haberkorn Identification and Evaluation of a New Tumor Cell-Binding Peptide, FROP-1 J. Nucl. Med., June 1, 2007; 48(6): 965 - 972. [Abstract] [Full Text] [PDF]

				T Kogai, K Taki, and G A Brent Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 797 - 826. [Abstract] [Full Text] [PDF]

				R. Elisei, A. Vivaldi, L. Agate, R. Ciampi, E. Molinaro, P. Piampiani, C. Romei, P. Faviana, F. Basolo, P. Miccoli, et al. All-Trans-Retinoic Acid Treatment Inhibits the Growth of Retinoic Acid Receptor {beta} Messenger Ribonucleic Acid Expressing Thyroid Cancer Cell Lines but Does Not Reinduce the Expression of Thyroid-Specific Genes J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2403 - 2411. [Abstract] [Full Text] [PDF]

				Y. Takiyama, N. Miyokawa, A. Sugawara, S. Kato, K. Ito, K. Sato, K. Oikawa, H. Kobayashi, S. Kimura, and M. Tateno Decreased Expression of Retinoid X Receptor Isoforms in Human Thyroid Carcinomas J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5851 - 5861. [Abstract] [Full Text] [PDF]

				D. K. Marsee, A. Venkateswaran, H. Tao, D. Vadysirisack, Z. Zhang, D. D. Vandre, and S. M. Jhiang Inhibition of Heat Shock Protein 90, a Novel RET/PTC1-associated Protein, Increases Radioiodide Accumulation in Thyroid Cells J. Biol. Chem., October 15, 2004; 279(42): 43990 - 43997. [Abstract] [Full Text] [PDF]

				Z. Liu, J. Falola, X. Zhu, Y. Gu, L. T. Kim, G. A. Sarosi, T. Anthony, and F. E. Nwariaku Antiproliferative Effects of Src Inhibition on Medullary Thyroid Cancer J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3503 - 3509. [Abstract] [Full Text] [PDF]

				C. Puppin, F. Arturi, E. Ferretti, D. Russo, R. Sacco, G. Tell, G. Damante, and S. Filetti Transcriptional Regulation of Human Sodium/Iodide Symporter Gene: A Role for Redox Factor-1 Endocrinology, March 1, 2004; 145(3): 1290 - 1293. [Abstract] [Full Text] [PDF]

				B. R. Haugen, L. L. Larson, U. Pugazhenthi, W. R. Hays, J. P. Klopper, C. A. Kramer, and V. Sharma Retinoic Acid and Retinoid X Receptors Are Differentially Expressed in Thyroid Cancer and Thyroid Carcinoma Cell Lines and Predict Response to Treatment with Retinoids J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 272 - 280. [Abstract] [Full Text] [PDF]